MLSS vs NVST vs PAIYY Stock Comparison

Milestone Scientific, Envista Holdings and Aesthetic Medical International Holdings Prices as of Oct 27, 2026 Peers: Industry group

Head to Head

5 decided of 12

Envista Holdings leads on 5 of the 12 questions below (Envista Holdings 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMLSSNVSTPAIYYLeader
Larger companyMarket capitalisation $28.45M $3.85B $491.09K NVST
Cheaper on earningsLower P/E, profitable companies only — 40.5x -0.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 15.7x — –
Faster revenue growthRevenue growth, trailing twelve months -27.5% +11.9% — NVST
More profitableNet margin, trailing twelve months — 3.3% — –
Better return on capitalReturn on invested capital — 2.5% — –
Less leveragedLower net debt / EBITDA — 0.8x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% — –
Better 1-year returnPrice return, last 12 months -31.9% +15.9% -95.2% NVST
Better 5-year returnAnnualised price return, 5 years -31.1%/yr -9.5%/yr -70.1%/yr NVST
Less volatileAnnualised volatility, 1 year 81.4% 37.8% 422.8% NVST
Higher overall scoreMean of the five percentile scores vs peers — 74/100 — –

Percentile Scorecard

MLSSNVSTPAIYY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMLSSNVSTPAIYY
Valuation – 97 #7 of 227 22 #72 of 92
Growth – 51 #109 of 219 –
Profitability – 74 #54 of 206 –
Financial Health – 52 #115 of 238 12 #86 of 97
Shareholder Returns – 96 #6 of 134 –
Overall – 74 –
  • MLSS ranked among 247 companies in Medical Devices and Diagnostics
  • NVST ranked among 247 companies in Medical Devices and Diagnostics
  • PAIYY ranked among 102 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMLSSNVSTPAIYYSPY
1 month -24.4%-1.6%-50.0% -0.2%
3 months -27.9%-12.6%-50.0% +3.9%
6 months -4.9%-11.0%-88.9% +8.2%
Year to date +13.6%+8.6%-94.1% +12.9%
1 year -31.9%+15.9%-95.2% +12.3%
3 years -65.1%+0.3%-98.3% +87.4%
3 years, per year -29.6%+0.1%-74.2% +23.3%
5 years -84.5%-39.3%-99.8% +67.9%
5 years, per year -31.1%-9.5%-70.1% +10.9%
10 years -83.2%—— +261.1%
10 years, per year -16.4%—— +13.7%

Risk

MeasureMLSSNVSTPAIYYSPY
Volatility, 1Y 81.4%37.8%422.8% 12.7%
Downside volatility, 1Y 83.3%34.6%1,222.1% 12.7%
Beta vs S&P 500, 1Y 1.291.14-3.75 1.00
Return / volatility, 1Y -0.390.42-0.23 0.97
Max drawdown, 5Y -90.9%-71.0%-99.8% -25.4%
From 52-week high -43.6%-22.1%-96.9% -1.2%
52-week high $0.55$30.26$0.32 $779.14
52-week low $0.25$18.95$0.01 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMLSSNVSTPAIYY
P/E now vs peer median —median 29.6x 40.2xmedian 29.6x -0.1xmedian 24.6x
P/S now vs peer median 4.2xmedian 2.9x 1.3xmedian 2.9x 0.0xmedian 1.6x
EV/EBITDA now vs peer median —median 17.4x 10.5xmedian 17.4x —median 14.6x
P/FCF now vs peer median —median 22.3x 15.3xmedian 22.3x -0.2xmedian 21.6x
P/B now vs peer median —median 2.3x 1.2xmedian 2.3x -0.1xmedian 3.2x
PEG now vs peer median —median 1.04 -1.81median 1.04 —median 0.66

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMLSSNVSTPAIYY
Revenue $6.58M $2.86B –
Gross profit – $1.58B –
Operating income – $273.60M –
Net income – $95.00M –
Free cash flow – $248.10M –
R&D – $120.80M –
EPS (diluted) – $0.58 –
Cash & equivalents – $1.13B $8.61M
Total debt – $1.44B $76.21M
Shares (diluted) 93.13M 164.10M 47.83M
Enterprise value $28.45M -$708.88M -$24.51M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMLSSNVSTPAIYY
P/E – 40.2x -0.1x
P/FCF – 15.3x -0.2x
P/Operating cash flow – 12.5x –
P/S 4.2x 1.3x 0.0x
P/B – 1.2x -0.1x
P/Tangible book – 1.5x -0.1x
EV/EBITDA – 10.5x –
EV/EBIT – 15.0x –
EV/Revenue 4.2x 1.4x –
EV/FCF – 16.5x –
EV/Operating cash flow – 13.5x –
PEG (3Y EPS CAGR) – -1.81 –

Growth

14 metrics
MetricMLSSNVSTPAIYY
Revenue growth (1Y) -27.5% 11.9% –
Revenue CAGR (3Y) -12.9% 3.4% –
Gross profit growth (1Y) – 13.1% –
Gross profit CAGR (3Y) – 2.3% –
Operating income growth (1Y) – 79.6% –
Operating income CAGR (3Y) – -4.4% –
Net income growth (1Y) – 76.6% –
Net income CAGR (3Y) – -24.0% –
EPS growth (1Y) – 82.8% –
EPS CAGR (3Y) – -22.2% –
Operating cash flow growth (1Y) – 3.6% –
Operating cash flow CAGR (3Y) – 8.8% –
Free cash flow growth (1Y) – -3.8% –
Free cash flow CAGR (3Y) – 15.8% –

Profitability

14 metrics
MetricMLSSNVSTPAIYY
Gross margin – 55.2% –
EBITDA margin – 13.6% –
Operating margin – 9.6% –
Pretax margin – 8.2% –
Net margin – 3.3% –
FCF margin – 8.7% –
Operating cash flow margin – 10.6% –
Return on equity – 3.1% –
Return on assets – 1.7% –
Return on invested capital – 2.5% –
Return on capital employed – 5.7% –
Asset turnover – 0.5x –
Cash conversion (OCF / net income) – 3.2x –
Stock comp / revenue – 1.4% –

Financial Health

11 metrics
MetricMLSSNVSTPAIYY
Debt / assets – 25.7% 28.2%
Debt / equity – 0.5x -3.3x
Net debt / EBITDA – 0.8x –
Debt / FCF – 5.8x –
Liabilities / assets – 45.0% 108.5%
Equity / assets – 55.0% -8.5%
Interest coverage – – –
Current ratio – 2.4x –
Quick ratio – 1.9x 0.3x
Cash ratio – 1.4x 0.1x
Altman Z-score – 1.73 –

Shareholder Returns

7 metrics
MetricMLSSNVSTPAIYY
Dividend yield – – –
Net buyback yield – 4.3% –
Shareholder yield – 4.3% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMLSSNVSTPAIYY
Forward P/E – 15.7xFY2026 –
EPS, next fiscal year $-0.04FY2026 $1.50FY2026 $-1.50FY2023
EPS growth, next FY – +26.1%FY2026 –
EPS growth, the year after – +16.7% –
Revenue, next fiscal year $9.29MFY2026 $2.99BFY2026 $89.98MFY2023
Revenue growth, next FY +3.6%FY2026 +9.8%FY2026 –
Revenue growth, the year after +27.1% +2.6% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMLSSNVSTPAIYY
Held by institutions 5.8% 100.0% –
Institutions holding 31 382 –
Change in shares held, QoQ +18.9% +6.4% –
Institutions buying 11 200 –
Institutions selling 4 129 –
Buyers to sellers 2.75 1.55 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MLSSNVSTPAIYY
MLSS 1.00 0.03 0.05
NVST 0.03 1.00 -0.06
PAIYY 0.05 -0.06 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MLSS, NVST and PAIYY?

Envista Holdings (NVST) is the largest by market capitalisation: Milestone Scientific (MLSS) $28.45M, Envista Holdings (NVST) $3.85B, Aesthetic Medical International Holdings (PAIYY) $491.09K.

Which company is growing faster?

Envista Holdings (NVST) grew revenue fastest over the trailing twelve months: Milestone Scientific (MLSS) -27.5%, Envista Holdings (NVST) +11.9%.

Which stock has performed better?

Over the past year Envista Holdings (NVST) returned the most: Milestone Scientific (MLSS) -31.9%, Envista Holdings (NVST) +15.9%, Aesthetic Medical International Holdings (PAIYY) -95.2%. Over five years, Envista Holdings (NVST) compounded fastest (Milestone Scientific (MLSS) -31.1%/yr, Envista Holdings (NVST) -9.5%/yr, Aesthetic Medical International Holdings (PAIYY) -70.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Envista Holdings (NVST) has been the steadiest (Milestone Scientific (MLSS) 81.4%, Envista Holdings (NVST) 37.8%, Aesthetic Medical International Holdings (PAIYY) 422.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MLSS, NVST and PAIYY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Envista Holdings (NVST) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.